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Endothelial cell injury and vascular function strongly correlate with cardiac function following ischemia/reperfusion injury. Several
studies indicate that endothelial cells are more sensitive to ischemia/reperfusion compared to cardiomyocytes and are critical
mediators of cardiac ischemia/reperfusion injury. H2S is involved in the regulation of cardiovascular system homeostasis and
can act as a cytoprotectant during ischemia/reperfusion. Activation of ERK1/2 in endothelial cells after H2S stimulation exerts
an enhancement of angiogenesis while its inhibition significantly decreases H2S cardioprotective effects. In this work, we
investigated how H2S pretreatment for 24 hours prevents the ischemia/reperfusion injury and promotes angiogenesis on
microvascular endothelial cells following an ischemia/reperfusion protocol in vitro, using a hypoxic chamber and ischemic
buffer to simulate the ischemic event. H2S preconditioning positively affected cell viability and significantly increased endothelial
cell migration when treated with 1μM H2S. Furthermore, mitochondrial function was preserved when cells were
preconditioned. Since ERK1/2 phosphorylation was extremely enhanced in ischemia/reperfusion condition, we inhibited ERK
both directly and indirectly to verify how H2S triggers this pathway in endothelial cells. Taken together, our data suggest that
H2S treatment 24 hours before the ischemic insult protects endothelial cells from ischemia/reperfusion injury and eventually
decreases myocardial injury.
1. Introduction
Cardiovascular diseases represent the leading cause of death
and disabilities in the industrialized countries, and ischemic
heart disease (IHD) majorly represents them. IHD causes
46% of cardiovascular deaths in men and 38% in women
worldwide [1]. One of the major challenges in treating the
ischemic heart is to avoid ischemia reperfusion injury (IRI);
the limitation of which can result of pivotal importance in
case of programmed ischemia/hypoxia such as open-heart
surgery, transplantation, or primary percutaneous coronary
intervention [2–4].
IRI is the trigger leading to cell death by apoptosis and
necrosis, and the causes of the activation of these phenomena
are mainly oxidative stress, inflammation, and intracellular
Ca2+ overload [5, 6]. In addition, reperfusion can also lead
to severe ventricular arrhythmia and, as a consequence, death
[7]. Low cardiac output, perioperative myocardial infarction,
and arrhythmias can, in turn, be the causes of I/R injury fol-
lowing cardiac surgery [8].
Paradoxically, the restoration of blood flow in the ische-
mic tissue can exacerbate the damage more than the ischemic
event itself, causing a phenomenon known as reperfusion
injury [2, 9]. Indeed, the restoration of coronary blood flow,
although necessary after the ischemic episode, leads to the
death of cardiac myocytes that were potentially viable at the
onset of reperfusion [10].
Since 1980, many important contributions shed light on
the importance of the endothelium in the cardiovascular sys-
tem, redirecting the investigating approach to the cardiovas-
cular system [5, 6, 11–16]. In the last 40 years, many advances
have been made toward a deeper comprehension of the role
of different cell types participating in the ischemic scenario
and the attention on ECs proportionally increased.
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In support to these findings, several studies indicate that
endothelial cells are as sensitive to ischemia/reperfusion as
cardiomyocytes and therefore are critical mediators of car-
diac IRI [17–22].
Furthermore, reoxygenation of the ischemic tissue causes
oxidative stress: during reperfusion, xanthine oxidase,
NADPH oxidase, and the mitochondrial electron transport
chain (mETC) generate reactive oxygen species (ROS), medi-
ating an increased myocardial injury [23, 24]. The above-
mentioned enzymes also provide the greatest amount of
superoxide anion in ECs [6].
During IRI, there is a deficiency of vasodilator molecules
such as endothelin [25], angiotensin, prostacyclin, and nitric
oxide, which directly influence metabolic and contractile
function in the adult heart [22, 26]. After the IR insult, ECs
undergo changes in cytoskeletal architecture and expression
of adhesion molecules (e.g., CAMs and E- and P-selectins).
The activation of quiescent ECs induces the recruitment of
neutrophils which initiate the inflammatory response. In par-
allel, ECs permeability increase resulting in the loss of barrier
function and capillary leakage [3, 5, 27].
The process of angiogenesis, which is de novo formation
of micro vessels, in pathological conditions is not only essen-
tial to prevent heart failure in the long term but also has the
potential to support the recovery of the ischemic myocar-
dium in the days following myocardial infarction. Impair-
ment of myocardial angiogenesis causes a reduction in
myocardial perfusion and fatal ischemic cardiomyopathy
[28–30]. Moreover, EC injury and vascular function strongly
correlate with the cardiac performance following IRI [31].
To prevent pathological remodeling in the structure of
blood vessels, ECs produce and release two endogenous gaso-
transmitters, hydrogen sulfide (H2S) and nitric oxide (NO).
In particular, H2S has been known for many years for being
a toxic agent. Nowadays, it is recognized as being a key factor
in the regulation of inflammatory and immune response, car-
diovascular and nervous systems, and gastrointestinal tract
function [32–35]. The cardiac tissue is capable of producing
H2S endogenously, due to the presence of a discreet quantity
of cystathionine-γ-lyase (CSE), one of the enzymes responsi-
ble for the production of this gasotransmitter [36]. H2S can
act as a cytoprotectant against oxidative stress and as an anti-
apoptotic agent by preserving mitochondrial function during
ischemia/reperfusion [37, 38].
The identification of the reperfusion injury salvage kinase
(RISK) pathway led the way to understand how to improve
the clinical outcomes of acute myocardial infarction by medi-
ating a programmed cell survival [9, 39, 40] when activated
specifically at the time of reperfusion [41]. The RISK pathway
is linked to two signaling cascades: PI3K-Akt and MEK1-
ERK1/2. Hu et al. observed not only that preconditioning
rat myocytes with NaHS (1–100μM) increased cell viability
but also that if ERK1/2 or Akt were blocked during precondi-
tioning or ischemia there was a significant decrease of the
H2S cardioprotective effect [42].
Studies on isolated rat liver mitochondria showed a
biphasic effect of H2S on mETC. Concentrations ranging
from 100nM to 1μM stimulated electron transport, whereas
10μM or higher provoked its inhibition [43]. The same
bimodal effect has been shown by Pupo et al., where H2S
induced no effect at the lowest and highest concentrations
(0.5 and 100μM) and a significant cellular response at 1μM
in terms of cell migration and proliferation [44].
Both PI3K-Akt and MEK-ERK1/2 pathways have been
demonstrated to be downstream effectors of H2S signaling
cascade also in ECs, thus promoting migration, proliferation,
and angiogenesis [35, 45–48].
Despite the growing literature in the field, it is still not
clear whether H2S could be more effective as a precondition-
ing or postconditioning agent [7, 19, 40, 42, 49, 50].
In our study, we decided to investigate the role of H2S as a
preconditioning trigger molecule, by using different micro-
molar concentrations of an inorganic H2S donor, namely,
sodium hydrosulfide (NaHS). Specifically, we investigated
whether a 24-hour treatment could trigger a cascade that
would enhance the endothelial response after an ischemic
insult in an in vitromodel of human microvascular endothe-
lial cells (HMEC-1). The in vitromodel is particularly feasible
to address functional recovery of ECs since it allows exposure
to hypoxia and drugs while maintaining the ability to prolif-
erate and migrate and, therefore, performing experimental
assays.
2. Materials and Methods
2.1. Cell Culture. Human microvascular endothelial cells 1
(HMEC-1) (ATCC® CRL3243™) were cultured in
EndoGRO™-MV Complete Culture Media Kit (Millipore)
and 1% penicillin/streptomycin (Pan Biotech) and passaged
80-90% confluence.
Dulbecco’s Modified Eagle’s Medium (DMEM) with phe-
nol red (Sigma-Aldrich) 2% FBS (Microgem), 1% penicillin/-
streptomycin, and 1% L-glutamine (Microgem) was used for
preconditioning and reoxygenation processes.
2.2. Hydrogen Sulfide Preconditioning and
Ischemia/Reperfusion Protocol. Sodium hydrosulfide hydrate
(NaHS) (Sigma-Aldrich) was used as a saline hydrogen sul-
fide donor. NaHS was freshly prepared in phenol red DMEM
2% FBS on the day of the experiment at a concentration of
5mM; the stock solution was used for dilutions to reach
our working conditions (1-10-100μM).
In vitro simulation of ischemia/reperfusion injury was
induced using an ischemic buffer (pH 6.2) as described in lit-
erature [25], and severe hypoxic conditions were reached
through incubation in a sealed chamber (see Scheme 1)
endowed with a regulator of gas mixture (InvivO2 200, Rus-
kinn, United Kingdom).
A minimum level of 1% O2 can be achieved by this sys-
tem, and no complete anoxia is guaranteed from the manu-
facturer. Moreover, to the best of our knowledge, 1% O2 at
atmospheric pressure matches the oxygen partial pressure
of ischemic tissues, including the myocardium [51]. The
buffer was equilibrated overnight in a hypoxic chamber (1%
O2, 5% CO2, 37
°C). CO2 levels were set to 5% to buffer pH
in medium, matching normoxic incubation. Cells were put
in the hypoxic chamber, and the medium was changed with
the equilibrated ischemic buffer. Ischemic protocol lasted
2 Oxidative Medicine and Cellular Longevity
for 2 hours in every experiment; cells were then reoxygenated
with fresh medium for 1 hour in a normoxic incubator (37°C,
5% CO2).
2.3. Solutions and Reagents
2.3.1. Ischemic Buffer. The buffer was freshly prepared before
each experiment. The following formulation was used: NaCl
137mM, KCl 12mM, MgCl2 0.49mM, CaCl2 0.9mM, HEPES
4mM, and Na L-lactate 20mM (all purchased from Sigma-
Aldrich). The ingredients were dissolved into double-distilled
water, and pH was adjusted to reach 6.2 before bringing the
solution to the required volume (100mL).
2.3.2. AZD6244. Also called Selumetinib, it is a selective
MEK1/2 inhibitor. The inhibitor was solubilized in DMSO,
as 10mM stock solutions at -20°C. The stock was diluted to
obtain a final concentration of 1μM.
2.3.3. SCH772984 (Aurogene). Selective ERK1/2 inhibitor was
dissolved in DMSO, as 5mM stock solutions at -80°C. The
stock was diluted to reach a working concentration of 1μM.
2.3.4. Antibodies. Primary antibodies anti-Heat-shock pro-
tein 90 (HSP90), p44/42 MAPK (ERK1/2), and phospho-
p44/42 MAPK (p-ERK1/2) were all purchased from Cell Sig-
naling Technology (The Netherlands). Secondary anti-rabbit
antibody was purchased from ImmunoReagents, Inc. (North
Carolina, USA). All antibodies were used according to the
manufacturer’s instructions.
2.4. Viability Assay. In order to address how cell viability
could be influenced by preconditioning, an MTT assay was
performed at 24 hours from the end of reoxygenation. Cells
were plated in a 96-well plate at a density of 0:5 × 104 cells/-
well in growth medium. On the next day, cells were precon-
ditioned as previously described. After 24 hours of
preconditioning, cells would undergo normoxic or IR condi-
tion following the ischemia/reperfusion protocol mentioned
earlier. At the end of reperfusion, media was changed for all
cells to DMEM 2% FBS, in order to keep cells alive for the
next 24 hours but avoiding cell proliferation. After one day,
MTT solution was added to each well (10μL/well), and plates
were kept in the dark in an incubator for 3 hours. Then,
media was removed and 100μL DMSO was added to each
well, and absorbance was detected at 570nm using a micro-
plate reader. At least eight wells for each condition were
analyzed.
2.5. Cell Migration Assay. To assess cell migration, cells were
plated into three-chamber silicone-culture inserts (Ibidi) in a
12-well plate at a density of 4 × 105 cells/mL in growth
medium. This density was chosen as the most appropriate
to have cells at 90-100% confluence overnight. On the next
day, cells were treated with NaHS as described before, by
removing the medium from each chamber and adding the
desired treatment or just control medium, being careful not
to scratch cells away. After 24 hours, all culture inserts were
removed, and cells were gently washed with warm PBS with
Ca/Mg. At this point, cells underwent IR protocol for 2
hours. At the end of the ischemia, cells were gently washed
with warm PBS and growth medium was added to each well.
After 6 hours of migration, cells were fixed in 4% PAF.
Images were then acquired using a Nikon Eclipse Ti-E micro-
scope with a ×10 lens. The MetaMorph software was used to
both acquire and analyze all images. Cell motility was
expressed as percentage of wound closure. At least three
fields for each condition were analyzed.
2.6. In Vitro Angiogenesis Assay. The formation of capillary-
like structures in vitro was studied on growth factor-reduced
Matrigel (Corning, USA). Matrigel was used according to the
manufacturer’s instructions. ECs were plated into Petri
dishes and treated according to our protocols on the follow-
ing day. After in vitro-simulated IR injury, cells were seeded
at 2:5 × 104 cells per well onto Matrigel-precoated 24-well
plate in growth medium. After 16 hours, cell organization
was observed using a 5x lens. Images were acquired using
the Infinity Analyze software (Lumenera Corporation). A
minimum of three fields was analyzed for each condition.
Image analysis was performed using ImageJ’s plugin
Angiogenesis Analyzer, which works on phase contrast
(RGB colors, 24 bit) or fluorescence images (8 or 16 bit). In
order to avoid artifacts, some background noise had to be
removed from the images using the “blurred mask tool.”
Once the image has been modified, the program can be run
and the images are automatically analyzed. The images are
returned with different paths traced in a color-code mode
and a table with different automatically measured parame-
ters. We choose to include in our analysis three parameters:
24h NaHS preconditioning




Incubator 5% CO2, 37ºC
NaHS 1-10-100 𝜇M or DMEM 2% FBS
Incubator 5% CO2, 37ºC
NaHS 1-10-100 𝜇M or DMEM 2% FBS
+ normoxic medium
Incubator
5% CO2, 37ºC1% O2, 5% CO2, 37ºC
+ normoxic medium
Hypoxic chamber
+ ischemic buffer pH 6.2
Scheme 1: Schematic representation of the experimental design used. On the upper side is represented the “normoxia” setting, whereas on the
lower panel is the setting used to simulate the in vitro “ischemia-reperfusion” condition.
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(I) number of master segments, (II) total master segment
length, and (III) number of isolated segments.
2.7. Quantification of Mitochondrial Mass and Membrane
Depolarization. To measure the depolarization of mitochon-
drial membrane in relationship with mitochondrial mass,
endothelial cells were plated at a density of 2 × 104 cells/well
on 1.5mm ø cover slips in growth medium. Cells were
treated as previously described (see Hydrogen Sulfide Pre-
conditioning and Ischemia/Reperfusion Protocol) with
1μM NaHS. After reperfusion, all specimens were incubated
in DMEM 2% FBS with both MitoTracker™ Green FM
(Thermo Fisher) 200 nM and MitoTracker™ Red CMXROS
(Thermo Fisher) 50 nM in the dark for 30 minutes at 37°C.
After staining, cells were washed with PBS and fixed with
4% PAF. After fixation, coverslips were mounted on micro-
scope slides and observed at a confocal microscope (Zeiss
LSM800) with a 63x oil-immersion objective. GMT has an
absorption/emission spectrum of 490 nm/516 nm, while the
RMT one is 579nm/599 nm. Images were acquired with
ZEN System software with a resolution of 512 × 512 pixels.
2.8. Western Blot. Cells were seeded into Petri dishes and
were allowed to reach confluence before being treated with
NaHS (1-10-100μM) and/or AZD6244 1μM and then
underwent IR simulation protocol. At the end of the proto-
col, cells were scraped and lysed with RIPA buffer (Sigma-
Aldrich), containing protease and phosphatase inhibitors
(Complete protease inhibitor tablets and PhosStop, Roche).
Whole cell lysates were separated by SDS-PAGE and wet-
transferred on PVDF membranes, according to the manufac-
turer’s protocol (Bio-Rad). After transfer, membranes were
blocked in 4% nonfat dried milk or 4% BSA (depending on
the primary antibody), for 1 hour at room temperature.
Membranes were washed once in TBST and incubated with
antibodies against HSP90 (1 : 1,000), ERK1/2 (1 : 1,000), and
phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
(1 : 1,000) overnight at 4°C. Membranes were washed with
TBST three times for 10min. Anti-rabbit secondary antibody
incubation (1 : 5,000) lasted for 1 hour. After another 30′ of
washing with TBST 1x, chemiluminescence was detected
using the ECL system (Bio-Rad) using a ChemiDoc Touch
instrument (Bio-Rad).
2.9. Image Analysis
2.9.1. Tubulogenesis Assay. During the analysis, we kept into
consideration the following parameters: number of master
segments, number of master junctions, total master segment
length, and number of isolated segments. A well-constructed
network should have more master elements (segments and
junctions), thus creating a more physiological and functional
structure. The images were analyzed with ImageJ’s Angio-
genesis Analyzer plugin, and only the aforementioned
parameters were kept into consideration. All images were
converted to RGB format if needed.
2.9.2. Mitochondrial Staining.Multichannel images were split
to separate the two channels. Then, the corrected total cell
fluorescence (CTCF) was calculated for each cell in both
channels as described in literature [52]. For each cell, the
ratio between mitochondrial depolarization and mass was
calculated and normalized on the control condition.
2.9.3. Image Lab Quantification. Using Image Lab software,
bands were detected automatically and then subtracting the
background to obtain a better quantification. Density of
bands was computed keeping into consideration the value
of the integrated density adjusted by subtracting the back-
ground. All proteins were quantified by normalizing the den-
sity over the loading control (HSP90).
2.10. Statistical and Computer Analysis. Results are expressed
as mean ± SEM. Differences between groups were analyzed
by one-way ANOVA or Kruskal-Wallis or Mann–Whitney
t-test. Significance was established at p value < 0.05. All raw
data were analyzed using Microsoft Excel and Prism 6. All
experiments were repeated at least three times.
3. Results
3.1. Biological Effects of NaHS Preconditioning. During acute
myocardial infarction, endothelial cells can go towards death
through apoptosis, necrosis, or autophagy [53–55]. To assess
endothelial cell response after IR injury in terms of viability,
an MTT assay was performed after 24 hours from the injury.
As shown in Figure 1, there was a decrease in the IR con-
dition compared to normoxia, but H2S did not significantly
increase cell viability in the post-IR condition.
The highest viability was observed at 10μM, but only in
normoxic conditions.
Cell migration is one of the essential processes during
angiogenesis. In fact, cells have to migrate to create new ves-
sels. The creation of new vessels is important after IR injury
in order to allow an adequate blood supply to the myocar-
dium and, eventually, to replace arteries that have been dis-
rupted by the ischemic event and subsequent reperfusion.
To study this process, we observed cell migration following
IR simulation. After 6 hours, the percentage of wound clo-
sure was calculated and compared to the normoxic control
condition (Figure 2(b)).
We observed a significant improvement of cell migration
in cells treated with NaHS, with the strongest effect at 1μM
NaHS, both in normoxia and post-IR.
To study whether NaHS treatment had a proangiogenic
effect on cells that underwent IR injury simulation, we stud-
ied their ability to form capillary-like structures in vitro
focusing on the most promising concentration of 1μM
NaHS.
After IR, cells were detached and plated in Matrigel-
precoated 24-well multiwell in EndoGRO 10% FBS for 16
hours. As shown in Figure 3, there is a positive trend in terms
of capillary formation in both normoxia and IR, upon treat-
ment of cells with 1μM NaHS, but no statistical significance
was observed.
We decided to perform a double MitoTracker™ stain-
ing on all samples to investigate whether mitochondria
were affected by NaHS preconditioning. MitoTracker™
Green FM stains all mitochondria, whereas MitoTracker™

































































































































Figure 2: (a) Representative images of cells after 6 hours in the different experimental conditions. (b) Relative migration, all data sets were
normalized on the normoxic control condition (CTRL). Statistical significance: ∗∗∗∗p < 0:0001.
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Red CMXROS stains only viable mitochondria. Red fluo-
rescence is directly proportional to membrane
depolarization.
By calculating the ratio between red and green fluores-
cence, we determined the influence of NaHS and IR on mito-
chondria in endothelial cells.
NaHS treatment decreased the mitochondrial mass with
a similar fashion in normoxia and IR (Figure 4(b)). However,
the mitochondrial function did not change much between
the two IR experimental conditions. On the other hand,
NaHS treatment caused an improvement in mitochondria
viability, observed as an increased ratio between vital (red)
and total (green) mitochondria, both in IR and normoxic
conditions (Figures 4(a)–4(d)).
3.2. NaHS Preconditioning and IR Injury Influence ERK1/2
Phosphorylation. Since ERK1/2 is deeply implicated in both
cell migration and angiogenesis, but also in inducing apopto-
sis, we evaluated whether IR and/or NaHS treatment could
influence its level of phosphorylation. Protein expression
and phosphorylation levels were assessed through western
blot.
ERK appeared to be strongly phosphorylated in IR condi-
tion, whereas NaHS treatment attenuated the p-ERK/ERK
ratio, bringing it towards a more physiological condition
(Figure 5).
3.3. Effects of MEK-ERK Pathway Inhibition. After assessing
the levels of ERK phosphorylation, we decided to investigate
if NaHS directly modulated the ERK pathway.
At first, we targeted its upstream modulator, MEK, using
its specific inhibitor AZD6244 before preconditioning. Both
viability and cell migration were tested.
Considering cell viability, there was no relevant differ-
ence with or without inhibitor and/or 1μM NaHS, confirm-
ing what we had already observed (see Figure 1).
When we tested the effects on cell migration, we con-
firmed the effect of preconditioning with 1μMNaHS in both
normoxia and IR. Moreover, we observed that the treatment
with MEK inhibitor only slightly decreased the rate of cell
migration compared to the control condition, especially in
normoxia. An even slighter effect was observed when we used
both the inhibitor and NaHS (Figure 6(b)).
After evaluating the effects on upstream inhibition, we
decided to investigate whether NaHS preconditioning could
rescue the biological effects after direct ERK1/2 inhibition.
Again, we assessed the inhibition on both cell viability
and cell migration, which are two key pathways in which
ERK1/2 is strongly involved.
No relevant changes were observed in IR condition, but a
significant decrease in cell viability was observed in normoxia





























































































































Figure 3: Quantification of main elements of the in vitro capillary network: (a) total master segment length; (b) number of master segments;
(c) number of junctions; (d) number of isolated elements.





































































































CTRL 1 𝜇M NaHS
(d)
Figure 4: (a) Ratio between red (RMT) and green (GMT) MitoTracker™; (b, c) GMT and RMT fluorescence, respectively, calculated for each
experimental condition as a percentage of CTRL; (d) representative fields of stained cells. All data sets were normalized on the normoxic
control condition (CTRL). Statistical significance: ∗∗p < 0:01, ∗∗∗p < 0:001, and ∗∗∗∗p < 0:0001.
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Focusing on cell migration, in normoxia, ERK inhibition
caused a significant decrease in cell migration, but NaHS
treatment was able to rescue this inhibition, restoring the
migration (Figure 7(b)). However, in IR, the direct inhibition
of ERK actually caused a very strong decrease in cell migra-
tion when compared to the IR untreated cells, which could
not be rescued by NaHS treatment (Figure 7(b)).
4. Discussion
Cardiovascular diseases are the leading cause of death world-
wide. In 2016, they represented up to 30% of all global deaths
[56, 57]. CVDs include different clinical conditions, most of
which are associated to a pathological condition known as
ischemia/reperfusion injury, such as myocardial infarction
and stroke [58–61]. Whether this phenomenon affects the
clinical outcome, it depends on the site, the duration, and
the severity of the ischemic event itself. Nevertheless, postis-
chemic reperfusion could exacerbate the damage both locally
and systemically. This paradox relies on an increase in
inflammatory response and, later on, to a profound tissue
injury [2]. During an ischemic insult, moreover, there are
several biochemical and cellular changes caused by the rapid
depletion of oxygen and nutrients that cells cannot bear alto-
gether with exacerbated effects during the reperfusion phase
[62–64].
Endothelial integrity is pivotal for a proper vasculariza-
tion which is, in turn, a key step for restoration of the physi-
ological state as demonstrated by the several complications
for patients undergoing incomplete cardiac revascularization
[65, 66]. In this regard, it is reported that endothelial cells are
very sensitive to IRI, even more than other cell types [20, 22,
27]. In addition, they are critical mediators for the onset of
the inflammatory response, the generation of ROS, and the
rapid restoration of the physiological pH.
In the ischemic myocardium, these events negatively
affect the surrounding tissue, exacerbating the reperfusion
injury and worsening the outcomes [2, 67].
A considerable part of literature about IRI has its focus on
cardiac cells, while a small amount of data is available about
endothelial cells, despite their importance in this context.
Considering the role of ECs in both injury and recovery after
the ischemic insult, the role of endothelial function in the
hypoxic/ischemic scenario is of scientific relevance to amelio-
rate tissue recovery.
To this end, the action of hydrogen sulfide as a protective
agent on endothelial cells against hypoxic/ischemic stress is
promising because of the recent description of its beneficial
effects in similar settings [68, 69]. H2S is known to act as a
secondary messenger [70, 71], and there is evidence that it
can be beneficial in IRI in several experimental models [72,
73]; hence, its potential as endogenous and exogenous thera-
peutic agent is gaining scientific attention. In order to study
the effects solely on the endothelium, we decided to use an
in vitro model of human microvascular endothelial cells to
test the direct effects of hydrogen sulfide as a preconditioning
agent, by using the inorganic donor NaHS. The aim was to
recover the physiological state after the ischemic event. In
particular, we expected to trigger a response in endothelial
cells that would last until the end of the ischemic event,
although NaHS is known to be rapidly hydrolyzed in water,
establishing equilibrium between H2S and S
2−+HS− species
[74].
The preconditioning phenomenon can play an important
role in the attenuation of ischemic consequences as demon-
strated by the modulation of angiogenic activity of ECs. We
verified this hypothesis by addressing the effects of H2S on
cell migration and the ability to create capillary-like struc-
tures in vitro. Data showed that 1μM NaHS pretreatment
in cells that underwent IR protocol was able to rescue the
defect in the migration rate, restoring the properties observed
in the control-normoxic condition. This finding suggests a
potential role of the gasotransmitter in promoting tissue
repair following IRI.
There is still open debate about the actual in vivo levels of












































Figure 5: (a) Representative experiment of ERK1/2 and p-ERK1/2; (b) ratio of p-ERK on total ERK (n = 4). Both total and phosphorylated
proteins were first normalized on the loading control (HSP90), and then, the ratio was calculated. All data sets were normalized on the
normoxic control condition (CTRL). Statistical significance: ∗∗∗∗p < 0:0001.
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conditions, the comparison of 2 putative concentrations (1
and 10μM) can help decipherer the biological effects of con-
stitutive deficiency. Low levels, 1μM NaHS, restored the
physiological condition in cell migration, whereas 10μM
gave a less intense increase in consistence with previously
described bimodal activities shown in other cell types [44].
These data contribute to the hypothesis that endogenous
and exogenous H2S, and their respective levels, might have
opposite effects on some important cellular functions.
Goubern et al. suggest that exogenous H2S could function
as an electron donor and as a potential inorganic energy
source in mammalian cells at low micromolar concentrations
[75]. The described mitoprotectant behavior could involve
mitochondrial biogenesis and dynamics, as demonstrated in
an endothelial model of rat aortic endothelial cells (RAEC)
in which exogenous H2S exerts antifission and promitophagy
effects when compared to the control in which endogenous
H2S is modulated [76]. An enhanced mitophagy could
explain diminished mitochondrial content in preconditioned
I/R cells compared to the untreated control (Figure 4).
Despite the decrease in the mitochondrial mass, the ratio
of functional mitochondria was enhanced in cells pretreated
with NaHS. These data could be explained by an H2S-medi-
ated enhancement of mitochondrial function and its sug-
gested role of ROS scavenger.
The next step was to understand whether a 24-hour pre-
conditioning could trigger a modulation of ERK phosphory-
lation, because of the role that the MEK/ERK pathway has in
endothelial cell migration, other than apoptosis. Most inter-
estingly, IR alone significantly enhanced ERK1/2 phosphory-
lation, while 1μM NaHS treatment managed to drastically




























































































































Figure 6: (a) Cell viability after MEK inhibition (1 μMAZD6244) and 1μMNaHS preconditioning. (b) Cell migration after MEK inhibition
(1 μM AZD6244) and 1μM NaHS preconditioning. Statistical significance: ∗p < 0:05, ∗∗p < 0:01, and ∗∗∗∗p < 0:0001.
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(CTRL) phosphorylation state. On the other hand, the treat-
ment did not affect ERK1/2 phosphorylation in normoxic
cells.
Last, since it appeared that ERK was modulated by the
NaHS treatment, we inhibited both ERK1/2 and its upstream
activator, MEK, with the selective inhibitors AZD6244 and
SCH772984. After testing the effects on cell viability and cell
migration, we observed that the direct inhibition of ERK, but
not MEK, decreased cell migration and could not be rescued
by H2S treatment, thus indicating that H2S modulates the
ERK pathway acting at the level of ERK phosphorylation.
Further experiments are needed to better describe the
involvement of this pathway activated 24 hours ahead of
the ischemic insult and how it is sustained over time. More-
over, it might be interesting to see whether the same concen-
trations could trigger similar effects in the postconditioning
window and what similarities the pre- and postconditioning
scenarios might have in common.
5. Conclusion
In our study, we showed that, despite its rapid metaboliza-
tion, H2S could be used as a long-term preconditioning agent
to ameliorate the effects of IRI. Moreover, this work is aimed
at investigating the role of H2S as a modulator of an ERK1/2-
dependent pathway, thus suggesting an important role for
microvascular endothelial cells to participate in the response
to ischemia/reperfusion injury. A deeper comprehension of

























































































































Figure 7: (a) Normalized viability after direct ERK1/2 inhibition (1 μM SCH772984) and 1μMNaHS preconditioning. (b) Cell migration on
1μM NaHS preconditioned cells after ERK1/2 inhibition (1 μM SCH772984). Statistical significance: ∗∗p < 0:01, ∗∗∗p < 0:001, and ∗∗∗∗p <
0:0001.
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better strategies to preserve and repair tissues after a hypox-
ic/ischemic insult.
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